Clareo Health | A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
BioNTech SE
With
Pfizer
Age
12–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Cohort 1: Participants 18 years of age or older.
Cohort 2: Participants 12 years of age or older.
Participants 12 through 64 years of age with at least 1 underlying medical condition that increases their risk of severe COVID-19.
You may not be if
History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s).
History of myocarditis or pericarditis.
Cohort 2: Receipt of a COVID-19 vaccine or a confirmed case of COVID-19 (confirmed by signs/symptoms and/or a positive test result based on local testing) less than 5 months (150 days) prior to study enrollment.
Refer to the study contact for further eligibility details.
